Granted Patent
B2
US 12,522,829 · App. 18/932,248 · Granted Jan 13, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.
Claims (4)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is 100% identical to SEQ ID NO: 4.
2 . The composition of claim 1 , wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.
3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is 100% identical to SEQ ID NO: 14.
4 . The composition of claim 3 , wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072083/0016 →
Continuity (2)
Division
18517808
· Nov 22, 2023
References Cited (54)
CA 2721333A1
· 2009
[cited by applicant]
CN 108998451A
· 2018
[cited by applicant]
Shang et al. Nature Reviews Genetics, vol. 24, p. 817; Jun. 28, 2023 (Year: 2023).
[cited by examiner]
Depieri et. al., European Journal of Pharmaceutics and Biopharmaceutics, vol. 105, p. 50-58; Aug. 2016 (Year: 2016).
[cited by examiner]
Yuan et. al., Molecular Medicine Reports, vol. 16, p. 2529-2537; Jul. 6, 2017 (Year: 2017).
[cited by examiner]
Teoh, et. al., Leukemia Research, vol. 40, p. 44-53; Jan. 2016 (Year: 2016).
[cited by examiner]
Denzler R et al., Mol Cell. Nov. 3, 2016;64(3):565-579 (Year: 2016).
[cited by examiner]
Gorski, S., Vogel, J. & Doudna, J., Nat Rev Mol Cell Biol 18, 215â228 (2017) (Year: 2017).
[cited by examiner]
Lam et al. 2015. Molec. Ther. Nuc. Ac. 4:e252 (Year: 2015).
[cited by examiner]
Van den Berg, et al., pp. 1-12, Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016).
[cited by examiner]
Ying et al. 2008. Mol. Biotechnol. 38:257â268 (Year: 2008).
[cited by examiner]
Teoh, H. et. al., Leukemia Research, vol. 40, Oct. 17, 2015. (Year: 2015).
[cited by examiner]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579.
[cited by applicant]
Zhang et al. “The risks of miRNA therapeutics: in a drug target perspective.” Drug design, development and therapy (2021): 721-733.
[cited by applicant]
Zhang et al. “Cytokines, inflammation, and pain.” International anesthesiology clinics 45.2 (2007): 27-37.
[cited by applicant]
WIPO translation of CN108998451 (2018).
[cited by applicant]
Asirvatham et al. “miRNA regulation of cytokine genes.” Cytokine 45.2 (2009): 58-69.
[cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016).
[cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228.
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
GenBank IL-1b mRNA Sequence (2023).
[cited by applicant]
GenBank IL-1b gene Sequence (2023).
[cited by applicant]
GenBank IL-18 mRNA Sequence (2023).
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
Fayyad-Kazan et al. “Downregulation of microRNA-24 and-181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes.” Human immunology 75.7 (2014): 677-685.
[cited by applicant]
Agarwal et al. “Predicting effective microRNA target sites in mammalian mRNAs.” elife 4 (2015): e05005.
[cited by applicant]
Li et al. “miR-190a-5p partially represses the abnormal electrical activity of SCN3B in cardiac arrhythmias by downregulation of IL-2.” Frontiers in Cardiovascular Medicine 8 (2022): 795675.
[cited by applicant]
Xu et al. “MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines.” Cancer cell international 10 (2010): 1-7.
[cited by applicant]
Lam et al. “siRNA versus miRNA as therapeutics for gene silencing.” Molecular therapy Nucleic acids 4 (2015).
[cited by applicant]
Ying et al. “The microRNA (miRNA): overview of the RNA genes that modulate gene function.” Molecular biotechnology 38 (2008): 257-268.
[cited by applicant]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402.
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
NCBI Search results for SEQ ID No. 5 2024.
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019;18(5):358-378. (Year: 2019).
[cited by applicant]
Momin et al., 2021, Cells, 10, 3097, p. 1-21 (Year: 2021).
[cited by applicant]